Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports

21-03-2024 | Breast Cancer | Review

Changes in Radiation Therapy: New Ultrahypofractionated Radiation, Repeat Breast Conservation Therapy in the Management of Breast Recurrence with Re-irradiation, Proton Therapy

Authors: Kristin M. Lupinacci, Quratulain (Anna) Sabih, Ria Mulherkar, John A. Vargo, Emilia J. Diego

Published in: Current Breast Cancer Reports

Login to get access

Abstract

Purpose of Review

Management of breast cancer is multidisciplinary, balancing local and systemic control between treatment modalities. Surgical, radiation, and medical therapies are combined to give the best prognosis. The goal of this review is to examine the advancements in radiotherapy in the treatment of breast cancer.

Recent Findings

Published data supports the shortening of radiation schedules through ultrahypofractionation and utilizing new energy sources through proton beam radiation. Emerging techniques have minimized radiation dosage to organs at risk and skin when compared to traditional radiation sources and plans. Traditionally an ipsilateral breast tumor recurrence after breast conservation therapy necessitated mastectomy. Re-irradiation is now an alternative option with comparable outcomes.

Summary

Advances in radiotherapy have contributed to more patients choosing breast-conserving surgery over mastectomy. This has prompted the investigation of alternative technologies and techniques to decrease toxicities, while maintaining oncologic efficacy
Literature
1.
Veronesi U, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11.PubMedCrossRef
2.
• Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16): 1227–32. After a 20-year median follow-up, there was no signficant difference in survival between women undergoing breast conservation therapy versus mastectomy.
3.
Fisher B, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665–73.PubMedCrossRef
4.
• Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41. With a 20-year follow-up, no significant survival benefit was seen between women undergoing lumpectomy followed by radiation versus mastectomy. A significant difference in ipsilateral breast tumor recurrence was seen between the lumpectomy alone versus lumpectomy followed by the radiation group.
5.
Tomkinson JG. Cauterization as an adjuvant to radiotherapy. Proc R Soc Med. 1908;1(Electro Ther Sect):83–92.
6.
Mc WR. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Br J Radiol. 1948;21(252):599–610.CrossRef
7.
Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.PubMedPubMedCentralCrossRef
8.
9.
Newmark JJ. 'No ordinary meeting’: Robert McWhirter and the decline of radical mastectomy. J R Coll Physicians Edinb. 2016;46(1):43–8.PubMedCrossRef
10.
Lodmell EA, Brady PR. Radiation therapy in breast cancer; a preliminary report on the application of a technique of the McWhirter type. Calif Med. 1951;75(5):354–8.PubMedPubMedCentral
11.
Fisher B, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6 Suppl):2827–39.PubMedCrossRef
12.
Fisher B, et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer. 1980;46(1):1–13.PubMedCrossRef
13.
14.
Mac Bride MB, et al. Factors associated with surgical decision making in women with early-stage breast cancer: a literature review. J Womens Health (Larchmt). 2013;22(3):236–42.PubMedCrossRef
15.
Clarke M, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRef
16.
17.
Nayyar A, Gallagher KK, McGuire KP. Definition and management of positive margins for invasive breast cancer. Surg Clin North Am. 2018;98(4):761–71.PubMedCrossRef
18.
Taghian A, et al. Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg. 2005;241(4):629–39.PubMedPubMedCentralCrossRef
19.
Blair SL, et al. Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons? J Am Coll Surg. 2009;209(5):608–13.PubMedCrossRef
20.
Azu M, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17(2):558–63.PubMedCrossRef
21.
Lovrics PJ, et al. Practice patterns and perceptions of margin status for breast conserving surgery for breast carcinoma: National Survey of Canadian General Surgeons. Breast. 2012;21(6):730–4.PubMedCrossRef
22.
• Moran MS, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):553–64. A meta-analysis evaluating optimal margin and ipsilateral breast tumor recurrence showed positive margins to be associated with double the risk of ipsilateral breast tumor recurrence. However, wider margins beyond no ink on the tumor do not significantly affect recurrence.
23.
• Morrow M, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016;6(5): 287–295. A meta-analysis evaluating optimal margin and ipsilateral breast tumor recurrence showed a 2-mm margin to significantly decrease the risk of recurrence compared with no ink on the tumor; however, wider margins greater than 2 mm did not affect recurrence.
24.
Kaczmarski K, et al. Surgeon re-excision rates after breast-conserving surgery: a measure of low-value care. J Am Coll Surg. 2019;228(4):504-512 e2.PubMedCrossRef
25.
Cochrane RA, et al. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003;90(12):1505–9.PubMedCrossRef
26.
Brands-Appeldoorn A, et al. Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy. Breast Cancer. 2022;29(1):114–20.PubMedCrossRef
27.
Salibian AA, Olson B, Shauly O, Patel KM. Oncoplastic breast reconstruction: principles, current techniques, and future directions. J Surg Oncol. 2022;126(3):450–9.PubMedCrossRef
28.
Audretsch W, Rezai M, Kolotas C, Zamboglou N, Schnabel T, Bojar H. Tumor-specific immediate reconstruction in breast cancer patients. Semin Plast Surg. 1998;11(1):71–100.CrossRef
29.
Agrawal RK, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93–100.PubMedCrossRef
30.
• Brunt AM, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020;38(28):3261–3272. With a 9.9-year median follow-up, there was no significant difference in normal tissue effects after a 20.5 Gy once weekly 5 Fx schedule compared with the traditional 50 Gy in 25 Fx; however, normal tissue effects were higher after 30 Gy in 5 Fx.
31.
• Murray Brunt A, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–1626. At a median follow-up of 71.5 months, 26 Gy in 5 Fx over 1 week was equivocal to the conventional schedule of 40 Gy in 15 Fx over 3 weeks in terms of local control and normal tissue effects.
32.
• Livi L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451–463. After a median follow-up of 5 years, there was no significant difference in ipsilateral breast tumor recurrence or survival between women receiving whole breast irradiation versus accelerated partial breast irradiation using intensity-modulated radiotherapy, with the accelerated partial breast irradiation group having less toxicity.
33.
Meattini I, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol. 2020;38(35):4175–83.PubMedCrossRef
34.
Coles CE, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048–60.PubMedPubMedCentralCrossRef
35.
Whelan TJ, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165–72.PubMedCrossRef
36.
Polgar C, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(2):259–68.PubMedCrossRef
37.
38.
Corrigan KL, et al. Adoption of ultrahypofractionated radiation therapy in patients with breast cancer. Adv Radiat Oncol. 2022;7(2): 100877.PubMedCrossRef
39.
40.
41.
Correa C, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9.PubMedCrossRef
42.
43.
Shah C, et al. Cost and cost-effectiveness of image guided partial breast irradiation in comparison to hypofractionated whole breast irradiation. Int J Radiat Oncol Biol Phys. 2019;103(2):397–402.PubMedCrossRef
44.
Khan AJ, et al. Nation-scale adoption of shorter breast radiation therapy schedules can increase survival in resource constrained economies: results from a Markov chain analysis. Int J Radiat Oncol Biol Phys. 2017;97(2):287–95.PubMedCrossRef
45.
Alpert TE, et al. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005;63(3):845–51.PubMedCrossRef
46.
Kaidar-Person O, Oldenborg S, Poortmans P. Re-irradiation and hyperthermia in breast cancer. Clin Oncol (R Coll Radiol). 2018;30(2):73–84.PubMedCrossRef
47.
Datta NR, et al. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–87.PubMedCrossRef
48.
Linthorst M, et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother Oncol. 2013;109(2):188–93.PubMedCrossRef
49.
Vernon CC, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996;35(4):731–44.PubMedCrossRef
50.
51.
Oldenborg S, et al. Reirradiation + hyperthermia for recurrent breast cancer en cuirasse. Strahlenther Onkol. 2018;194(3):206–14.PubMedCrossRef
52.
Arthur DW, et al. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-year toxicity report from a phase 2 study of repeat breast-preserving surgery and 3-dimensional conformal partial-breast reirradiation for in-breast recurrence. Int J Radiat Oncol Biol Phys. 2017;98(5):1028–35.PubMedPubMedCentralCrossRef
53.
Arthur DW, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):75–82.PubMedCrossRef
54.
Fattahi S, et al. Reirradiation for locoregional recurrent breast cancer. Adv Radiat Oncol. 2021;6(1): 100640.PubMedCrossRef
55.
56.
57.
Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: review of a fifteen-year experience. Technol Cancer Res Treat. 2006;5(2):81–9.PubMedCrossRef
58.
• Bush DA, et al. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. Int J Radiat Oncol Biol Phys. 2014;90(3):501–5. With a median follow-up of 60 months, this data supports the use of proton beam radiation to deliver partial breast irradiation in patients with early-stage breast cancer, with equivalent oncologic and improved cosmetic outcomes, attributed to skin-sparing immobilization techniques.
59.
Kozak KR, et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66(3):691–8.PubMedCrossRef
60.
Olivotto IA, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31(32):4038–45.PubMedCrossRef
61.
Taylor CW, et al. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015;93(4):845–53.PubMedCrossRef
62.
Lin LL, et al. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. Acta Oncol. 2015;54(7):1032–9.PubMedCrossRef
63.
• Hassan MZO, et al. Serial measurement of global longitudinal strain among women with breast cancer treated with proton radiation therapy: a prospective trial for 70 patients. Int J Radiat Oncol Biol Phys. 2023;115(2):398–406. This study assessed global longitudinal strain and cardiac enzymes in women undergoing proton radiation therapy, which predict cardiac events and subsequent mortality. There were no changes in any of these values after proton radiation therapy, improved from prior studies reporting cardiac effects after traditional photon radiation.
64.
Lo Q, et al. Subclinical cardiac dysfunction detected by strain imaging during breast irradiation with persistent changes 6 weeks after treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):268–76.PubMedCrossRef
65.
Trivedi SJ, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148–54.PubMedCrossRef
66.
Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol. 2013;106(1):42–9.PubMedCrossRef
67.
Raptis A, et al. Cancer risk after breast proton therapy considering physiological and radiobiological uncertainties. Phys Med. 2020;76:1–6.PubMedCrossRef
68.
Tommasino F, et al. Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery. Acta Oncol. 2017;56(5):730–6.PubMedCrossRef
69.
Thorpe CS, et al. Proton beam therapy reirradiation for breast cancer: multi-institutional prospective PCG registry analysis. Breast J. 2019;25(6):1160–70.PubMedCrossRef
70.
Austin AM, et al. Individualised selection of left-sided breast cancer patients for proton therapy based on cost-effectiveness. J Med Radiat Sci. 2021;68(1):44–51.PubMedCrossRef
71.
•• De la Cruz Ku G, et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 2022;29(10):6163–6188. This meta-analysis included over 1.5 million breast cancer patients undergoing both mastectomy and breast-conserving surgery followed by radiation, which showed patients undergoing breast conservation therapy were found to have an overall survival benefit compared to the mastectomy group. The explanation for this improvement in survival has been hypothesized but is likely multifactorial.
Metadata
Title
Changes in Radiation Therapy: New Ultrahypofractionated Radiation, Repeat Breast Conservation Therapy in the Management of Breast Recurrence with Re-irradiation, Proton Therapy
Authors
Kristin M. Lupinacci
Quratulain (Anna) Sabih
Ria Mulherkar
John A. Vargo
Emilia J. Diego
Publication date
21-03-2024
Publisher
Springer US
Published in
Current Breast Cancer Reports
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-024-00544-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits